Chimeric Therapeutics Toekomstige groei
Future criteriumcontroles 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Chimeric Therapeutics.
Belangrijke informatie
n/a
Groei van de winst
n/a
Groei van de winst per aandeel
| Biotechs winstgroei | 15.2% |
| Inkomstengroei | n/a |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 08 Apr 2024 |
Recente toekomstige groei-updates
Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 6/30/2025 | N/A | -21 | N/A | -17 | 1 |
| 6/30/2024 | 7 | -13 | -8 | -8 | N/A |
| 3/31/2024 | 10 | -12 | -8 | -8 | N/A |
| 12/31/2023 | 12 | -12 | -8 | -8 | N/A |
| 9/30/2023 | 8 | -19 | -12 | -12 | N/A |
| 6/30/2023 | 5 | -26 | -16 | -16 | N/A |
| 3/31/2023 | 5 | -22 | -18 | -18 | N/A |
| 12/31/2022 | 6 | -18 | -20 | -20 | N/A |
| 9/30/2022 | 4 | -17 | -17 | -16 | N/A |
| 6/30/2022 | 3 | -16 | -14 | -13 | N/A |
| 3/31/2022 | 1 | -19 | -15 | -13 | N/A |
| 12/31/2021 | N/A | -21 | -16 | -13 | N/A |
| 9/30/2021 | N/A | -18 | -15 | -11 | N/A |
| 6/30/2021 | N/A | -15 | -14 | -9 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: Insufficient data to determine if CHM's forecast earnings growth is above the savings rate (2.4%).
Winst versus markt: Insufficient data to determine if CHM's earnings are forecast to grow faster than the Australian market
Hoge groeiwinsten: Insufficient data to determine if CHM's earnings are expected to grow significantly over the next 3 years.
Omzet versus markt: Insufficient data to determine if CHM's revenue is forecast to grow faster than the Australian market.
Hoge groei-inkomsten: CHM is forecast to have no revenue next year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if CHM's Return on Equity is forecast to be high in 3 years time